Samsung Bioepis cancer drug under review by FDASamsung Bioepis said Wednesday that the U.S. Food and Drug Administration has begun reviewing its license application for a cancer-fighting biosimilar called SB3.
A biosimilar is a drug with active properties similar to a previously licensed one. SB3 references Herceptin, a breast cancer drug from Swiss pharmaceutical company Roche.
According to Samsung Bioepis, SB3 is the company’s first oncological biosimilar submitted for regulatory review in the United States.
By Kim Jee-hee
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)